
SECOND ANNOUNCEMENT

34th Symposium on Medicinal Chemistry in Eastern England



Thursday 27th April, 2023 Fielder Centre, Hatfield, UK





#HatfieldMedChem23

Synopsis

Known colloquially as the "Hatfield MedChem" meeting, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.

Programme

09:00 REGISTRATION / COFFEE

MORNING SESSION

Chair: Simon Ward, Medicines Discovery Institute, Cardiff University, UK

- 09:30 Welcome and Introduction
- 09:40 Identification of H4R Antagonist HTL0032547 as a potential therapy for Atopic Dermatitis Charlotte Fieldhouse, Heptares, UK
- 10:20 Optimisation of aminofurazans leading to orally bioavailable and CNS penetrant inhibitors of MSK-1 (Mitogen and Stress-Activated Kinase 1) Anne Valade, UCB, Belgium
- 11:00
- 11:30 Isoform-Selective EPAC Activators: Therapeutic Opportunities for Cardiopulmonary Inflammation Graeme Barker, Heriot-Watt University, UK
- 11:55 Discovery of novel LpxA inhibitors targeting Pseudomonas aeruainosa Alastair Parkes, Evotec, UK
- 12:20 Electrostatic Complementarity in Structure-Based Drug Design James Day, Astex, UK

12.45

AFTERNOON SESSION

Chair: Margarita Puente-Felipe, GSK, Spain

- 14:15 Next Generation Antibody-Drug Conjugates David Spring, Cambridge University, UK
- 14:55 Al-driven approach to the discovery of novel Mpro inhibitors with high pan-coronavirus activitv Marco Derudas, ExScientia, UK
- 15:20 REFRESHMENTS
- 15:50 Combining surface chemistry with affinity selection mass spectrometry accelerates drug discovery for protein and oligonucleotide targets Zachary Gurard-Levin, SAMDI Tech a Charles River company, US
- 16:15 Discovery and Optimisation of Potent and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations Clare Thomson, AstraZeneca, UK
- 16.55 **Concluding Remarks**
- 17:00 Meeting Close

Organising Committee



Adrian Hall UCB (Treasurer)

Secretariat contact: Hg3 Conferences



Nicole Hamblin Charles River (Chair)



Sponsors













To find out more, visit the BMCS website by using the URL or by scanning the QR code here: www.rscbmcs.org/events/mcee-2/

events@hg3.co.uk +44 (0) 1423 529333

